Trials / Conditions / CD55-deficient Protein-losing Enteropathy
CD55-deficient Protein-losing Enteropathy
3 registered clinical trials studyying CD55-deficient Protein-losing Enteropathy.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Completed | Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy ( NCT04209634 | Regeneron Pharmaceuticals | Phase 2 / Phase 3 |
| Approved For Marketing | Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy NCT06003881 | Regeneron Pharmaceuticals | — |
| Approved For Marketing | Compassionate Use of Pozelimab NCT05232110 | Regeneron Pharmaceuticals | — |